Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
To determine the effect of a novel gut microbiota-targeted therapeutic regimen (bowel lavage
and antibiotics with or without an antifungal) in the management of active Crohn's Disease
(CD) that is refractory to conventional, immunosuppressive therapy.
Phase:
Phase 2
Details
Lead Sponsor:
University of Pennsylvania
Collaborators:
Children's Hospital of Philadelphia Crohn's and Colitis Foundation